Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy

Journal of Urology

Volumn 160, Issue 4, 1998, Pages 1291-1296

  Jahnson, S ^a   Karlsson, M G ^a  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

Bladder; Cystectomy; Prognosis; Protein p53; Retinoblastoma protein

Indexed keywords

PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0032323980     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62518-7     Document Type: Article

References (31)

1. Levine, A. J., Momand, J. and Finlay, C. A.: The p53 tumor suppressor gene. Nature, 351: 453, 1991.
2. Nouri, A. M. E., Darakhshan, F., Cannell, H., Paris, A. M. and Oliver, R. T.: The relevance of p53 mutation in urological malignancies: possible clinical implications for bladder cancer. Brit. J. Urol., 78: 337, 1996.
3. Reznikoff, C. A., Belair, C. D., Yeager, T. R., Savelieva, E., Blelloch, R. H., Puthenveettil, J. A. and Cuthill, S.: A molecular genetic model of human bladder cancer pathogenesis. Sem. Oncol., 23: 571, 1996.
4. Miyamoto, H., Shuin, T., Torigoe, S., Iwasaki, Y. and Kubota, Y.: Retinoblastoma gene mutations in primary human bladder cancer. Brit. J. Cancer, 71: 831, 1995.
5. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S.-C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl. J. Med., 331: 1259, 1994.
6. Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C. and Scher, H. I.: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol., 13: 1384, 1995.
7. Kuczyk, M. A., Bokemeyer, C., Serth, J., Hervartin, C., Oelke, M., Höfner, K., Tan, H. K. and Jonas, U.: p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur. J. Cancer, 31A: 2243, 1995.
8. Lipponen, P. K.: Over-expression of P53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365, 1993.
9. Underwood, M. A., Reeves, J., Smith, G., Gardiner, D. S., Scott, R., Bartlett, J. and Cooke, T. G.: Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Brit. J. Urol., 77: 659, 1996.
10. Wu, C. S., Pollack, A., Czerniak, B., Chyle, V., Zagars, G. K., Dinney, C. P., Hu, S. X. and Benedict, W. F.: Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology, 47: 305, 1996.
11. Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W. R., Fuks, Z. and Reuter, V. E.: Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Cancer Inst., 84: 1251, 1992.
12. Logothetis, C. J., Xu, H. -J., Ro, J. Y., Hu, S. X., Sahin, A., Ordonez, N. and Benedict, W. F.: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer Inst., 84: 1256, 1992.
13. Wright, C., Thomas, D., Mellon, K., Neal, D. E. and Horne, C. H.: Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index. Brit. J. Urol., 75: 173, 1995.
14. Ye, D. W., Zheng, J. F., Qian, S. X. and Ma, Y. J.: Expression of p53 product in Chinese human bladder carcinoma. Urol. Res., 21: 223, 1993.
15. Hall, P. A. and Lane, D. P.: p53 in tumor pathology: can we trust immunohistochemistry? - Revisited! (Editorial). J. Path., 172: 1, 1994.
16. McKee, P. H., Hobbs, C. and Hall, P. A.: Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology, 23: 377, 1993.
17. Lambkin, H. A., Mothersill, C. M. and Kelehan, P.: Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J. Path., 172: 13, 1994.
18. Ishikawa, J., Xu, H. -J., Hu, S. -X., Yandell, D. W., Madea, S., Kamidono, S., Benedict, W. F. and Takahashi, R.: Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res., 51: 5736, 1991.
19. Xu, H. -J., Cairns, P., Hu, S, -X., Knowles, M. A. and Benedict, W. F.: Loss of RB protein expression in primary bladder cancer correlates with the loss of heterozygosity at the RB locus and tumor progression. Int. J. Cancer, 53: 781, 1993.
20. Cote, R. J., Esrig, D., Groshen, S., Jones, P. A. and Skinner, D. G.: p53 and treatment of bladder cancer (Letter to the Editor). Nature, 385: 123, 1997.
21. Jahnson, S., Risberg, B., Karlsson, M. G., Westman, G., Bergström, R. and Pedersen, J.: p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur. Urol., 28: 135, 1995.
22. Moch, H., Sauter, G., Mihatsch, M. J., Gudat, F., Epper, R. and Waldman, F. M.: p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum. Path., 25: 1346, 1994.
23. Thomas, D. J., Robinson, M. C., Charlton, R., Wilkinson, S., Shenton, B. K. and Neal, D. E.: P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Brit. J. Urol., 73: 533, 1994.
24. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. F., Herr, H. W. and Reuter, V. E.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker of disease progression. J. Natl. Cancer Inst., 85: 53, 1993.
25. Ogura, K., Habuchi, T., Yamada, H., Ogawa, O. and Yoshida, O.: Immunohistochemical analysis of p53 and proliferative cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity. Int. J. Urol., 2: 302, 1995.
26. Esrig, D., Spruck, C. H., III, Nichols, P. W., Chaiwun, B., Steven, K., Groschen, S., Chen, S. -C., Skinner, D. G., Jones, P. A. and Cote, R. J.: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Amer. J. Path., 143: 1389, 1993.
27. Vet, J. A. M., Bringuier, P. P., Schaafsma, H. E., Witjes, J. A., Debruyne, F. M. J. and Schalken, J. A.: Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab. Invest., 73: 837, 1995.
28. Wynford-Thomas, D.: P53 in tumour pathology: can we trust immunocytochemistry? (Editorial). J. Path., 166: 329, 1992.
29. Cairns, P., Proctor, A. J. and Knowles, M. A.: Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene, 6: 2305, 1991.
30. Waldman, T., Kinzler, K. W. and Vogelstein, B.: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res., 55: 5187, 1995.
31. Giannikaki, E., Kouvidou, C., Tzardi, M., Stefanaki, K., Koutsoubi, K., Gregortiou, M., Zois, E., Kakolyris, S., Mavroudi, C., Delides, G., Georgoulias, V. and Kanavaros, P.: p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1. Anticancer Res., 17: 2123, 1997.